UPLC for Synthetic Peptides: A User`s Perspective

Similar documents
LC and LC/MS Column Selection Flow Chart

APPLICATIONS TN Peptide Purification Method Development: Application for the Purification of Bivalirudin. Introduction

Transferring Yesterdays Methods to Tomorrows Technology: The Evolution from HPLC to UPLC TM

Successfully Scaling and Transferring HPLC and UPLC Methods

Simultaneous Determination of Pharmaceutical Peptides and Acetate Counterions by HPLC Using a Mixed-Mode Weak Anion-Exchange Column

LC Technical Information

1.7µm Fortis C18 UHPLC Columns

Streamlining the Analysis of Oral Contraceptives Using the ACQUITY UPLC H-Class System

Kromasil Eternity Designed for long life

A Quality by Design (QbD) Based Method Development for the Determination of Impurities in a Peroxide Degraded Sample of Ziprasidone

UPLC Method Development and Validation

Peptide Isolation Using the Prep 150 LC System

Automating Method Development with an HPLC System Optimized for Scouting of Columns and Eluents

Product Bulletin. ACE LC/MS and Rapid Analysis HPLC Columns. HPLC Columns

USP Method Transfer and Routine Use Analysis of Irbesartan Tablets from HPLC to UPLC

Supporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2007

Use of Ultra-High Performance LC-MS for Challenging Assays. David Browne, Laboratory Manager (LC-MS-MS), Covance Laboratories, Harrogate

Agilent s New Weak Anion Exchange (WAX) Solid Phase Extraction Cartridges: SampliQ WAX

Validation of ACQUITY UPLC Methods

Quality control analytical methods- Switch from HPLC to UPLC

Assay Transfer from HPLC to UPLC for Higher Analysis Throughput

Integrated approach to HPLC method development: Using all the tools in the chromatographer s toolbox

Kromasil Eternity Designed for long life. For use in HPLC and UHPLC

Overcome Top Challenges in Analytical Method Development and Validation

ANALYSIS OF BASIC COMPOUNDS

Analysis of Positional Isomers of Lapatinib with Agilent Poroshell 120 PFP Columns

2.1 2,3 Dichloro Benzoyl Cyanide (2,3 DCBC) and survey of. manufactured commonly for the bulk drug industry, few references were

The Depsipeptide Methodology for Solid Phase Peptide Synthesis: Circumventing Side Reactions and Development of an Automated Technique via

ACE SuperC18. ACE UHPLC and HPLC Columns. Ultra-Inert UHPLC and HPLC Columns with Extended ph Stability

Application Note. Author. Abstract. Pharmaceutical QA/QC. Siji Joseph Agilent Technologies, Inc. Bangalore, India

HICHROM. Chromatography Columns and Supplies. LC COLUMNS SIELC Primesep. Catalogue 9. Hichrom Limited

SUPPORTING INFORMATION

Basic Principles for Purification Using Supercritical Fluid Chromatography

DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS

Prep 150 LC System: Considerations for Analytical to Preparative Scaling

8. Methods in Developing Mobile Phase Condition for C18 Column

Dilution(*) Chromatography

Postsynthetic modification of unprotected peptides via S-tritylation reaction

Too Polar for Reversed Phase What Do You Do?

Online Reaction Monitoring of In-Process Manufacturing Samples by UPLC

ACD/AutoChrom Assisted Method Development for Challenging Separations. Vera Leshchinskaya February 7, 2018

Kromasil Eternity Designed for long life

Agilent 1290 Infinity Quaternary LC Stepwise Transfer to Methods with MS-Compatible Mobile Phases

ACQUITY UPLC Peptide BEH C 18, 130Å and 300Å Columns

Routine MS Detection for USP Chromatographic Methods

Welcome to our E-Seminar: Choosing HPLC Columns for Faster Analysis Smaller and Faster

Comparison of different aqueous mobile phase HPLC techniques

Modernizing the USP Monograph for Acetaminophen

Supporting Information for. PNA FRET Pair Miniprobes for Quantitative. Fluorescent in Situ Hybridization to Telomeric DNA in Cells and Tissue

DEMONSTRATING SUPERIOR LINEARITY: THE ACQUITY UPLC PHOTODIODE ARRAY DETECTOR

High Performance Liquid Chromatography. Table 1: Allowed HPLC Adjustment of USP <621> and EP <2.2.46>

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

The Secrets of Rapid HPLC Method Development. Choosing Columns for Rapid Method Development and Short Analysis Times

Packings for HPLC. Packings for HPLC

Supporting Information

Utilizing ELSD and MS as Secondary Detectors for Prep HPLC and Flash Chromatography. Tips and Techniques to Optimize ELSD and MS based Purification

ACE SuperC18. ACE UHPLC and HPLC Columns. Ultra-Inert UHPLC and HPLC Columns with Extended ph Stability

The Use of the ACQUITY QDa Detector for a Selective, Sensitive, and Robust Quantitative Method for a Potential Genotoxic Impurity

Implementation of Methods Translation between Liquid Chromatography Instrumentation

Choosing Columns and Conditions for the Best Peak Shape

Acclaim Mixed-Mode WCX-1

A Plausible Model Correlates Prebiotic Peptide Synthesis with. Primordial Genetic Code

viridis Columns Bringing a New Dimension to SFC Combining state-of-the-art media manufacturing with industry leading column technology, Viridis

ACE Excel SuperC18. ACE UHPLC and HPLC Columns. Ultra-Inert UHPLC and HPLC Columns with Extended ph Stability

Eliminating Unwanted Variability in LC Methods: More Uptime, More Sample Throughput

ACE. For increased polar retention and alternative selectivity. Alternative selectivity for method development

columns Acclaim Mixed-Mode WCX-1 for Separating Basic Molecules

1.7 m Fortis UHPLC Columns

VALIDATION OF A UPLC METHOD FOR A BENZOCAINE, BUTAMBEN, AND TETRACAINE HYDROCHLORIDE TOPICAL SOLUTION

2007 Waters Corporation. Application of UPLC to Peptide Mapping

GB Translated English of Chinese Standard: GB NATIONAL STANDARD OF THE

LC Columns with Liquid Separation Cell Technology

Automatization for development of HPLC methods

Figure 1. Structures for Vitamin B2 and Vitamin B1.

Scaling Up to Preparative Chromatography

Reversed Phase Solvents

A Workflow Approach for the Identification and Structural Elucidation of Impurities of Quetiapine Hemifumarate Drug Substance

Luna 2.5 µm C18(2)-HST. Advantages of 2.5 µm for increasing the speed of analysis while maintaining high efficiency

Agilent LC & LC-MS Cannabis Testing

Figure 1. Structures for Vitamin B2 and Vitamin B1.

Supporting Information. A fluorogenic assay for screening Sirt6 modulators

Acclaim Mixed-Mode WAX-1 Columns

Inertsil ODS-EP Technical Information

Thermo Scientific. Anion-Exchange Column. Determination of Inorganic Anions in Diverse Sample Matrices. Superior Chromatographic Performance

[ CARE AND USE MANUAL ]

Supporting Information

for Acclaim Mixed-Mode WCX-1

for Acclaim Trinity TM P1

William E. Barber, Ph.D. Applications Chemist October

How to Troubleshoot a Failed System Suitability Test

Method Development Kits

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

penta-hilic UHPLC COLUMNS

Analysis - HPLC A.136. Primesep 5 µm columns B.136

The new Agilent 1290 Infinity Quaternary LC

Separation of Explosives in EPA 8330: Column Choices Optimize Speed, Resolution, and Solvent Use. Application. Authors. Abstract.

Application Note. Pharmaceutical QA/QC. Author. Abstract. Siji Joseph Agilent Technologies, Inc. Bangalore, India

New Approaches in the Analysis of Amadori Compounds

Cation Exchange HPLC Columns

New Product Update. HPLC Columns

Transcription:

Tides 2007 Conference Las Vegas, May 23, 2007 UPLC for Synthetic Peptides: A User`s Perspective Holger Hermann, Jens Donath* Lonza AG, Switzerland

Welcome to Lonza! One of the leading CMO Production facilities worldwide Europe USA Asia Switzerland Belgium Czech Republic UK Spain China Singapore slide 2

QC Tasks at Lonza Visp Method Development Method Validation & Transfer Support of R&D Activities Structure elucidation Raw material Testing In-Process Testing (24/7) Release Testing of finished Products Cleaning (Swab / Rinse) Stability Testing slide 3

Options for Speed Other techniques (NMR, etc) New instruments/columns UPLC / <2μm types Method improvements Combination of all PAT / Online analytics Optimize workflow More resources (FTE, instruments) slide 4

Why UPLC? Use of smaller particles (< 2 µm) + speed up of analysis (higher flow rates) + higher sensitivity (less peak broadening) + better resolution (more theoretical plates/length) - higher back pressure (due to smaller particles) slide 5

Need for Speed Peptide synthesis Crude protected peptide Deprotection of peptide Purified peptide Purification of peptide Crude unprotected peptide more than once Decision on OK pool Fraction control Preparative HPLC slide 6

UPLC Fraction Control 1 8-mer 0.070 0.060 0.050 0.040 0.030 0.020 UPLC 2 times faster runtime 3-4 x higher intensity better resolution 1.566 0.3 % impurity 99.0 % pure 17.403 17.857 18.393 UPLC method runtime 32 min. flow : 0.25 ml / min. column : Waters Acquity BEH Shield 0.3 % impurity 22.092 22.437 RP18, 2.1x100mm, 1.7µm 25.154 25.351 25.959 26.138 26.495 0.000 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 0.020 0.018 0.016 0.014 0.012 0.008 0.006 0.004 2.466 1 0.3 % impurity 98.9 % pure 20.086 20.824 21.442 21.875 2 29.613 3 37.254 4 5 41.752 42.118 HPLC method runtime 68 min. flow : 1 ml / min. column: Waters XBridge Shield RP18, 4.6x150mm, 3.5µm 0.002 0.000 0.2 % impurity -0.002 0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00 52.00 54.00 56.00 58.00 60.00 62.00 64.00 66.00 68.00 slide 7

UPLC Fraction Control 1 8-mer 0.034 0.032 0.030 0.028 0.026 0.024 0.022 0.020 0.018 UPLC 2 times faster runtime 3-4 x higher intensity better resolution 0.016 0.014 0.012 0.008 15.625 16.159 18.520 18.653 19.186 20.870 21.455 21.634 21.783 22.773 23.403 23.633 23.780 19.650 22.157 24.325 24.563 24.690 24.750 20.406 24.121 17.863 22.485 22.536 22.995 24.468 0.006 0.004 0.002 0.000 15.00 15.50 16.00 16.50 17.00 17.50 18.00 18.50 19.00 19.50 20.00 20.50 21.00 21.50 22.00 22.50 23.00 23.50 24.00 24.50 25.00 0.035 0.030 0.025 0.020 0.015 0.005 0.000-0.005 17.00 18.00 19.00 20.00 21.00 22.00 23.00 24.00 25.00 26.00 27.00 28.00 29.00 30.00 31.00 32.00 33.00 34.00 35.00 36.00 37.00 38.00 39.00 40.00 slide 8 17.475 17.641 22.765 23.221 23.757 24.472 26.164 26.802 28.672 30.649 35.690 36.515 36.920 37.973 38.210 39.705 29.797 31.246 20.813 37.502 HPLC

UPLC Fraction Control 2 Cyclic 9-mer 0.024 0.022 0.020 0.018 0.016 0.014 0.012 HPLC SFI-323-PG1-33.112 52.476 HPLC Release Method Phenomenex Synergi MAX-RP C18 250x4.6mm, 4mm 0.008 13.356 50.825 0.006 0.004 0.002 12.674 14.601 15.758 17.982 18.894 20.759 26.421 27.558 28.205 29.793 30.907 31.595 35.900 39.415 41.070 42.090 46.529 48.911 49.900 51.900 52.967 53.325 54.099 54.662 0.000-0.002-0.004 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00 52.00 54.00 Run time >60min Resolution of critical impurities needed Column not UPLC compatible Solution for IPC 2 separate methods, dedicated instruments slide 9

UPLC Fraction Control 2 Cyclic 9-mer 0.050 0.048 0.046 0.044 0.042 0.040 0.038 0.036 HPLC MP-003-22.066 23.838 IPC A Waters Symmetry Shield RP8 250x4.6mm, 5μm 0.034 0.032 0.030 0.028 21.269 22.976 24.111 0.026 0.024 0.022 0.020 0.018 17.812 21.736 22.493 22.713 23.449 24.324 24.886 26.162 0.016 0.014 0.012 0.008 0.006 17.00 17.50 18.00 18.50 19.00 19.50 20.00 20.50 21.00 21.50 22.00 22.50 23.00 23.50 24.00 24.50 25.00 25.50 26.00 26.50 27.00 27.50 28.00 28.50 29.00 29.50 30.00 0.060 0.055 0.050 0.045 HPLC SFI-323-TG1-16.491 IPC B Agilent Zorbax C8 150x4.6mm, 3.5μm 0.040 0.035 18.287 0.030 17.951 0.025 0.020 14.620 17.422 0.015 14.197 14.302 15.109 15.321 15.511 15.722 15.833 16.185 16.911 17.034 17.235 17.714 18.598 18.721 18.990 19.311 19.397 19.508 19.886 19.959 20.385 0.005 12.50 13.00 13.50 14.00 14.50 15.00 15.50 16.00 16.50 17.00 17.50 18.00 18.50 19.00 19.50 20.00 20.50 21.00 slide 10

Speed and Resolution! 0.024 0.022 0.020 0.018 HPLC 0.016 0.014 0.012 0.008 0.006 0.004 0.002 0.000-0.002-0.004 0.015 0.014 10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00 52.00 54.00 0.013 0.012 0.011 0.009 0.008 0.007 0.006 0.005 0.004 0.003 0.002 0.001 0.000-0.001 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 HPLC Release Method Phenomenex Synergi MAX-RP C18 250x4.6mm, 4mm UPLC IPC Method Waters BEH C18 100x2.1mm, 1.7mm same to better resolution than release 3 x faster slide 11 5.010 5.253 6.972 7.867 10.270 4.124 14.153 16.250 4.375 15.802 16.667 16.710 17.383 17.315 17.493 17.632 17.843 16.925 17.133 13.246 UPLC 12.674 15.758 14.601 17.982 18.894 20.759 26.421 27.558 28.205 29.793 30.907 31.595 35.900 39.415 41.070 46.529 42.090 48.911 49.900 51.900 52.967 53.325 54.099 54.662 13.356 50.825 52.476 SFI-323-PG1-33.112

Need for Resolution Peptide synthesis Crude protected peptide Deprotection of peptide Purified peptide Purification of peptide Crude unprotected peptide Impurity Profile slide 12

Impurity Profile I 20mer LC / MS (TOF) experiments to analyze for co-eluting compounds M 7 M 9 M 1 M 2 M 3 M 4 M 5 M 6 M 10 M 11 M 8 M 12 slide 13

Impurity Profile II A/D Converter Channel 1 from 11433_01.wiff Intensity, % 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 wrong isomer e.g. D-isomer M 8 -Tyr M W target peptide M 7 M 2 -Pro M 1 +Gly / -Leu/Ile starting material M 3 M 4 +Tyr 2.7 2.6 deletion 2.5 2.4 2.3 2.2 M 6 + Leu M 5 +Gly double hit 2.1 2.0 9.0 10.0 11.0 12.0 13.0 14.0 15.0 16.0 17.0 18.0 19.0 20.0 21.0 22.0 23.0 24.0 25.0 26.0 27.0 28.0 29.0 30.0 Time, min slide 14

Results HPLC for Column I TM-001 0.015 0.014 0.013 0.012 0.011 0.009 0.008 0.007 0.006 0.005 target peptide TM-001_+2Pro impurity 4 TM-001_2Gly impurity 5 TM-001_+Pro TM-001_6Gly TM-001_+Tyr impurity 2 TM-001_3Gly impurity 3 impurity 1 impurity 6 0.004 0.003 0.002 0.001 0.000-0.001-0.002-0.003 15.20 15.40 15.60 15.80 16.00 16.20 16.40 16.60 16.80 17.00 17.20 17.40 17.60 17.80 18.00 18.20 18.40 18.60 slide 15

Results HPLC for Column II 0.015 0.014 0.013 0.012 0.011 0.009 0.008 TM-001_+2Pro TM-001_+Pro TM-001_6Gly TM-001_2Gly TM-001_+Tyr impurity 1 impurity 2 TM-001_3Gly TM-001 0.007 0.006 0.005 target peptide impurity 4 impurity 3 impurity 5 impurity 6 0.004 0.003 0.002 0.001 0.000-0.001-0.002-0.003 10.00 10.20 10.40 10.60 10.80 11.00 11.20 11.40 11.60 11.80 12.00 12.20 12.40 12.60 12.80 13.00 13.20 13.40 13.60 13.80 14.00 slide 16

HPLC Method Development Column Screening Waters XTerra, XBridge (C18) Jupiter Proteo (C12) Synergi (C18) Discovery HS (C18), RP-Amide (C16) SunFire C8, Sunfire 18 Kromasil C4 ZirChrom Carb (polare phase) Lichrospher NH 2 YMC ODS AQ C18 anion / cation exchange columns etc. Different buffer systems ammonium acetate phosphate buffer perchlorate buffer ammonium bicarbonate buffer Different ph ph 2, ph 7, ph 10 Different organic solvents acetonitrile methanol slide 17

HPLC / Optimized 0.072 0.070 0.068 0.066 0.064 0.062 0.060 0.058 0.056 0.054 0.052 0.050 0.048 0.046 0.044 0.042 0.040 0.038 0.036 0.034 0.032 0.030 0.028 0.026 0.024 0.022 0.020 0.018 0.016 0.014 0.012 18.167 18.853 19.083 19.417 19.961 20.212 20.912 impurity 1 21.433 target peptide impurity 2 22.382 22.873 23.328 impurity 6 impurity 7 impurity 8 impurity 3 24.233 flow 1.0 ml / min. sodium acetate RP C18 300 Å 250 x 4.6mm, 5 μm 24.677 impurity 4 25.840 26.463 impurity 5 26.999 8 minutes 5 impurities 27.882 0.008 18.00 18.50 19.00 19.50 20.00 20.50 21.00 21.50 22.00 22.50 23.00 23.50 24.00 24.50 25.00 25.50 26.00 26.50 27.00 27.50 28.00 slide 18

UPLC / Optimized 0.015 0.014 0.013 0.012 0.011 0.009 impurity 1 19.598 20.499 target peptide impurity 3 21.118 flow 0.25 ml / min. perchlorate buffer Acquity UPLC BEH C18 150 x 2.1mm, 1.7 μm 0.008 0.007 0.006 0.005 0.004 impurity 2 20.019 impurity 4 21.544 impurity 5 21.813 impurity 6 22.048 imprity 7 22.347 impurity 8 23.214 0.003 0.002 0.001 19.143 19.826 20.282 22.728 4 minutes 8 impurities 0.000-0.001-0.002 18.00 18.20 18.40 18.60 18.80 19.00 19.20 19.40 19.60 19.80 20.00 20.20 20.40 20.60 20.80 21.00 21.20 21.40 21.60 21.80 22.00 22.20 22.40 22.60 22.80 23.00 23.20 23.40 23.60 23.80 24.00 24.20 24.40 slide 19

Transfer HPLC UPLC: Tools Waters UPLC calculator (http://www.waters.com/calc) HPLC Calculator v1.0 Developed by J.-L. VEUTHEY, D. GUILLARME, Laboratory of Analytical Pharmaceutical Chemistry, University of Geneva (http://www.unige.ch/sciences/pharm/fanal/divers/downloads.php) slide 20

HPLC Calculator v1.0 slide 21

Transfer HPLC UPLC: Our learnings Easy to transfer for small molecules (less impurities, therefore resolution usually less critical) Easy to transfer if same column type is used Otherwise: Peak assignment might become an issue (impurity markers/ms detection advantageous) More resolution potentially more peaks Transfer tools are helpful, but do not replace experts QA accepted transfer concept slide 22

UPLC Small Molecules - Pseudoproline 0.030 0.025 0.020 0.015 FMOC-Ala-Thr(Ψ MeMe pro)-oh 9.992 98.96 area % HPLC Waters XBridge C18 5.0µm, 4.6x150 mm) Inj. vol. 10 μl flow 1.0 ml/min. 0.005 0.43 5.018 0.04 6.725 0.17 7.460 7.657 0.08 0.09 9.531 0.22 12.868 0.000-0.005 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 16.00 17.00 18.00 19.00 20.00 0.030 0.025 0.020 0.015 0.005 0.000 shorter run time better resolution easy transfer 0.43 1.302 0.02 1.786 0.15 2.001 2.170 0.10 0.08 2.578 2.926 99.01 area % 0.21 4.000 UPLC Acquity UPLC BEH C18 1.7µm, 2.1x100 mm Inj. vol. 1.4 μl flow 0.61 ml/min. -0.005-0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 slide 23

HPLC/UPLC - Adjustment or Change? Adjustment no re-validation proven by robustness studies Guidance: FDA ORA Laboratory Procedure #ORA-LAB.5.4.5. Revised 09/09/2005 USP Guidance drafted (e.g. Pharmacopeial Forum 31(6), 1681, 2005) Change re-validation not proven by robustness study FDA Drafted Guidance Mostly Draft Guidance, therefore to be discussed with QA Literature: M. Swartz, I. Krull, LCGC, 24(8), 770 (2006) slide 24

Adjustments Parameter ph Buffer Salt Concentration Ratio of components in the mobile phase UV Detector Wavelength Column Length Column Inner diameter Flow Rate Injector volume Particle Size Column Temperature max. Variance ± 0.2 units ±10% Components specified at 50% or less: ±30% or ±2% absolute No Deviations ±70% ±50% (ORA) ±50% Reduced as far as consistent with accepted precision and detection limits Reduced by as much as 50% ±20% - gradient adjustments? - column chemistry? - compensation for gradient delay times? slide 25

Changes Comparability Protocol The comparability protocol would be designed to demonstrate that the proposed changes in the analytical procedures improve or do not significantly change characteristics used in methods validation that are relevant to the type of analytical procedure (e.g., accuracy, precision, specificity, detection limit, quantitation limit, linearity, range) Reference: Guidance for Industry: Comparability Protocols Chemistry, Manufacturing, and Controls Information (http://www.fda.gov/cder/gmp/5427dft.pdf) slide 26

Summary UPLC powerful tool to save time in IPC. UPLC powerful tool to gain resolution for process development/improvement. Transferring HPLC to UPLC methods easy and straight forward if the same column type is used. Transferring HPLC to UPLC methods easy and straight forward for small molecules. Transferring HPLC to UPLC methods for synthetic peptides sometimes rises addition questions (peak assignment, coeluting peaks). MS detection very helpful. slide 27

Thank you for your attention!